We start this week with two deals between European biotechs and larger Japanese companies. Belgium’s Ogeda struck … Verona Pharma filed for an $86 million Nasdaq IPO to fund mid-phase trials in chronic obstructive pulmonary disease and cystic fibrosis.
( read original story …)